Camillo G. Porta
Bari, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 432 publications
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: July 01, 2026
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.
Journal: European urology open science
Published: June 08, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).
Journal: Minerva urology and nephrology
Published: April 23, 2026
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: March 23, 2026
Multimodal predictions of end stage chronic kidney disease from asymptomatic individuals for discovery of genomic biomarkers.
Journal: BMC nephrology
Published: February 23, 2026
Discovering Predictive Biomarkers in Renal Cell Carcinoma.
Journal: European urology oncology
Published: February 17, 2026
Identification of Predictive Genomic Biomarkers in Metastatic Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis of Real-World Clinicogenomic Data.
Journal: JCO precision oncology
Published: January 23, 2026
Outcomes of Complete Responders From First-line Therapy in Metastatic Renal Cell Carcinoma in the Real World: An Analysis From the International Metastatic Renal Cell Carcinoma Database Consortium.
Journal: Clinical genitourinary cancer
Published: January 15, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 23, 2025
Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma.
Journal: Clinical genitourinary cancer
Published: December 15, 2025
Last Updated: 09/26/2026